Holen Sie sich die Stockscreener-App
0.39
1.13%
-0.008
Schlusskurs vom Vortag:
$0.398
Offen:
$0.411
24-Stunden-Volumen:
34,554
Relative Volume:
0.07
Marktkapitalisierung:
$15.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.67M
KGV:
-0.1262
EPS:
-3.09
Netto-Cashflow:
$-101.06M
1W Leistung:
+0.90%
1M Leistung:
-3.55%
6M Leistung:
-12.26%
1J Leistung:
-88.22%
1-Tages-Spanne:
$0.387
$0.413
1-Wochen-Bereich:
$0.38
$0.413
52-Wochen-Spanne:
$0.2195
$3.51
Athira Pharma Inc Stock (ATHA) Company Profile
Firmenname
Athira Pharma Inc
Sektor
Branche
Telefon
(425) 620-8501
Adresse
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Vergleichen Sie ATHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.39 | 15.50M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.57 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
462.95 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.83 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
656.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.29 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-04 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-09-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Herabstufung | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-10-17 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-06-23 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Herabstufung | Jefferies | Buy → Hold |
| 2022-06-23 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Eingeleitet | BTIG Research | Buy |
| 2022-04-21 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Goldman | Neutral |
| 2020-10-13 | Eingeleitet | Goldman | Buy |
| 2020-10-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-13 | Eingeleitet | Jefferies | Buy |
| 2020-10-13 | Eingeleitet | Stifel | Buy |
Alle ansehen
Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten
Applying Elliott Wave Theory to Athira Pharma Inc.Earnings Overview Summary & Consistent Return Strategy Ideas - Newser
Has Athira Pharma Inc. found a price floorJuly 2025 Market Mood & Fast Exit Strategy with Risk Control - Newser
What moving averages say about Athira Pharma Inc.Market Sentiment Report & Entry Point Confirmation Alerts - Newser
Is Athira Pharma Inc. a candidate for recovery playPortfolio Profit Report & Low Risk Profit Maximizing Plans - Newser
What does recent volatility data suggest for Athira Pharma Inc.CPI Data & Long-Term Growth Plans - Newser
Athira Pharma Reports Reduced Losses Amid Financial Challenges - MSN
Momentum Screeners Rank Athira Pharma Inc. in Top 5 Today2025 Trading Recap & Reliable Breakout Stock Forecasts - Newser
Price momentum metrics for Athira Pharma Inc. explainedJuly 2025 Summary & Precise Trade Entry Recommendations - Newser
Ichimoku Cloud Indicates Uncertainty Around Athira Pharma Inc.2025 Stock Rankings & Weekly Top Performers Watchlists - beatles.ru
Can momentum traders help lift Athira Pharma Inc.Quarterly Earnings Report & Entry and Exit Point Strategies - Newser
How to build a dashboard for Athira Pharma Inc. stockEarnings Beat & Reliable Trade Execution Plans - Newser
Sentiment analysis tools applied to Athira Pharma Inc.July 2025 Market Mood & Safe Swing Trade Setups - Newser
Is Athira Pharma Inc. building a consolidation baseEarnings Trend Report & High Conviction Investment Ideas - Newser
Elliott Wave Theory Predicts Pullback in Athira Pharma Inc.2025 Top Gainers & Safe Capital Growth Tips - beatles.ru
Investors Can Still File Late Claims in Athira Pharma Settlement — Here’s How to Get Your Share - TradingView
Will Athira Pharma Inc. rebound enough to break evenJuly 2025 Snapshot & Free Technical Pattern Based Buy Signals - Newser
Exit strategy if you’re trapped in Athira Pharma Inc.July 2025 Weekly Recap & Fast Entry and Exit Trade Plans - Newser
Can machine learning forecast Athira Pharma Inc. recoveryMarket Trend Summary & Free Expert Approved Momentum Trade Ideas - Newser
Athira Pharma Inc. Earnings Report Breakdown: What Investors Should KnowTrade Signal Summary & Risk Adjusted Buy and Sell Alerts - Newser
Will Athira Pharma Inc. benefit from AI trendsQuarterly Market Summary & Momentum Based Trading Ideas - classian.co.kr
Athira Pharma Inc. stock prediction for this week2025 Market WrapUp & Risk Controlled Daily Plans - Newser
What is the cash position of Athira Pharma Inc.Market Activity Summary & Fast Moving Trade Plans - kangso.co.kr
Will Athira Pharma Inc. face regulatory challenges2025 Momentum Check & Reliable Breakout Stock Forecasts - sundaytimes.kr
Traders Consider Averaging Down in Athira Pharma Inc.2025 AllTime Highs & Weekly Hot Stock Watchlists - sundaytimes.kr
Athira Pharma presents results from Phase 1 trial of ATH-1105 at ALS Nexus - MSN
Athira Pharma shares rise 2.01% after-hours after presenting positive Phase 1 trial results for ATH-1105. - AInvest
How to monitor Athira Pharma Inc. with trend dashboardsPortfolio Gains Summary & Technical Confirmation Trade Alerts - Newser
Reversal Confirmed Athira Pharma Inc. Stock Rallies Above MAJuly 2025 Fed Impact & Weekly Watchlist of Top Performers - classian.co.kr
Athira Pharma Inc. At Decision Level — Rebound or ResistancePortfolio Value Summary & Low Risk Profit Maximizing Plans - sundaytimes.kr
Athira Pharma Inc. Tests 50 Day MA After Sharp DeclineJuly 2025 Setups & High Accuracy Trade Signal Alerts - metrotimes.co.kr
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 - GlobeNewswire
Athira Pharma reports positive Phase 1 results for ALS drug candidate - Investing.com Nigeria
Novel Oral ALS Drug Candidate ATH-1105 Demonstrates Favorable Safety Profile in Early Trial - Stock Titan
Are Bears Losing Grip on Athira Pharma Inc.Portfolio Value Summary & Verified Chart Pattern Trade Signals - classian.co.kr
Athira Pharma Inc. Testing Reversal Zone on Weekly ChartRecession Risk & Accurate Technical Buy Alerts - 선데이타임즈
Finanzdaten der Athira Pharma Inc-Aktie (ATHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Athira Pharma Inc-Aktie (ATHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
168,901 |
| Litton Mark James | President and CEO |
Jun 30 '25 |
Option Exercise |
0.00 |
108,334 |
0 |
350,925 |
| Litton Mark James | President and CEO |
Jul 01 '25 |
Sale |
0.29 |
25,123 |
7,374 |
325,802 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
46,666 |
0 |
82,507 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jul 01 '25 |
Sale |
0.29 |
10,842 |
3,182 |
71,665 |
| Worthington Mark | General Counsel and CCO |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
120,401 |
| Worthington Mark | General Counsel and CCO |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
111,875 |
| Renninger Robert | SVP, Finance and Accounting |
Jun 30 '25 |
Option Exercise |
0.00 |
12,359 |
0 |
112,083 |
| Renninger Robert | SVP, Finance and Accounting |
Jul 01 '25 |
Sale |
0.29 |
2,897 |
850 |
109,186 |
0.97%
0.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):